No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
C.Q. Pharmaceutical Holding Co., Ltd. (SZSE:000950) Screens Well But There Might Be A Catch
Heavy Pharmaceuticals Holdings: 2024 Annual Results Forecast
C.Q. Pharmaceutical Holding (000950.SZ) issued a profit warning, expecting net income between 0.29 billion yuan and 0.39 billion yuan, a year-on-year decline of 40.45% to 55.72%.
C.Q. Pharmaceutical Holding (000950.SZ) disclosed its performance forecast for 2024, with the company expecting profits attributable to Shareholders of the listed company...
C.Q. Pharma's Unit Gets Drug Registration Certificate for Mirabegron Tablets
C.Q. Pharmaceutical Holding (000950.SZ): C.Q. Pharmaceutical has received the pharmaceutical registration certificate for Mirabegron extended-release tablets.
On January 9, Gelonghui reported that C.Q. Pharmaceutical Holding (000950.SZ) announced that its subsidiary, Chongqing Pharmaceutical (Group) Co., Ltd. (referred to as "C.Q. Pharmaceutical"), recently received the Pharmaceutical registration certificate for Mirabegron Sustained-release Tablets approved by the National Medical Products Administration. Mirabegron Sustained-release Tablets were developed by Astellas Pharma Europe B.V., first launched in Japan in September 2011 under the trade name Betanis; approved by the FDA in the USA in June 2012, under the trade name Myrbetriq.
The Returns At C.Q. Pharmaceutical Holding (SZSE:000950) Aren't Growing
